Effect of Iovastatin on expression of Bcl-2 family proteins and viability in purified tumor cells derived from myeloma patients
Patient . | Mcl-1 . | Bcl-XL . | Bcl-2 . | Bax . | Viability . |
|---|---|---|---|---|---|
| 1 | 3.7 | 86.8 | 103.1 | 76.7 | 18.4 |
| 2 | 4.8 | 33.0 | 144.9 | 181.5 | 18.9 |
| 3 | 21.8 | 69.7 | 103.7 | 92.5 | 60 |
| 4 | 2.3 | 112.0 | 95.0 | 98.7 | 23.7 |
| 5 | 3.3 | 82.5 | 101.5 | 76.9 | 4.6 |
Patient . | Mcl-1 . | Bcl-XL . | Bcl-2 . | Bax . | Viability . |
|---|---|---|---|---|---|
| 1 | 3.7 | 86.8 | 103.1 | 76.7 | 18.4 |
| 2 | 4.8 | 33.0 | 144.9 | 181.5 | 18.9 |
| 3 | 21.8 | 69.7 | 103.7 | 92.5 | 60 |
| 4 | 2.3 | 112.0 | 95.0 | 98.7 | 23.7 |
| 5 | 3.3 | 82.5 | 101.5 | 76.9 | 4.6 |
Purified myeloma cells were treated with solvent control or 30 μM Iovastatin for 4 days. After protein isolation, Mcl-1, Bcl-XL, Bcl-2, and Bax were detected by Western blot analysis. Protein levels were quantitated by densitometry analysis of the protein bands and expressed as a percentage of the solvent control values. The percentage of viable cells, relative to the solvent control-treated cells, was measured by using MTT assay.